BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

863 related articles for article (PubMed ID: 16345019)

  • 1. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of methods for futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2005 Sep; 24(18):2747-64. PubMed ID: 16134130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing the sample size when the unblinded interim result is promising.
    Chen YH; DeMets DL; Lan KK
    Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of futility in clinical trials.
    Snapinn S; Chen MG; Jiang Q; Koutsoukos T
    Pharm Stat; 2006; 5(4):273-81. PubMed ID: 17128426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Over-ruling a group sequential boundary--a stopping rule versus a guideline.
    Lan KK; Lachin JM; Bautista O
    Stat Med; 2003 Nov; 22(21):3347-55. PubMed ID: 14566919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Informing the selection of futility stopping thresholds: case study from a late-phase clinical trial.
    Hughes S; Cuffe RL; Lieftucht A; Garrett Nichols W
    Pharm Stat; 2009; 8(1):25-37. PubMed ID: 18383194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A composite design for transition from a preliminary to a full-scale study.
    Lachin JM; Younes N
    Stat Med; 2007 Nov; 26(27):5014-32. PubMed ID: 17577245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stopping clinical trials early for benefit: impact on estimation.
    Freidlin B; Korn EL
    Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type I error in sample size re-estimations based on observed treatment difference.
    Shun Z; Yuan W; Brady WE; Hsu H
    Stat Med; 2001 Feb; 20(4):497-513. PubMed ID: 11223896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The type II error probability of a group sequential test of efficacy and futility, and considerations for power and sample size.
    Dobbins TW
    J Biopharm Stat; 2013 Mar; 23(2):378-93. PubMed ID: 23437945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample size re-estimation in group-sequential response-adaptive clinical trials.
    Morgan CC
    Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive design and estimation in randomized clinical trials with correlated observations.
    Yin G; Shen Y
    Biometrics; 2005 Jun; 61(2):362-9. PubMed ID: 16011682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The reassessment of trial perspectives from interim data--a critical view.
    Bauer P; Koenig F
    Stat Med; 2006 Jan; 25(1):23-36. PubMed ID: 16220517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of experiments with adaptive interim analyses.
    Bauer P; Köhne K
    Biometrics; 1994 Dec; 50(4):1029-41. PubMed ID: 7786985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment.
    Whitehead J; Matsushita T
    Stat Med; 2003 Mar; 22(5):677-87. PubMed ID: 12587099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stopping boundaries adjusted for sample size reestimation and negative stop.
    Shun Z
    J Biopharm Stat; 2002 Nov; 12(4):485-502. PubMed ID: 12477071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A general statistical principle for changing a design any time during the course of a trial.
    Müller HH; Schäfer H
    Stat Med; 2004 Aug; 23(16):2497-508. PubMed ID: 15287080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal conditional error functions for the control of conditional power.
    Brannath W; Bauer P
    Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.